Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia

Table 2

Distribution of use of each pharmacological group of QT-prolonging drugs.

Medication group	Total patients; ()	% within the QT group
Nervous system	224140	63.0
Opioids	164651	46.3
Anesthetics, general	62951	17.7
Psychotropic drugs (antiparkinson drugs, psycholeptics, and psychoanaleptics)	39582	11.1
Alimentary tract and metabolism	202046	56.8
Anti-infectives for systemic use	46238	13.0
Antibacterials for systemic use	35683	10.0
Antimycotics for systemic use	3611	1.0
HIV (antivirals for systemic use)	556	0.2
Cardiovascular system	41564	11.7
Diuretics	40098	11.3
Antiarrhythmics	3794	1.1
Systemic hormonal preparations, excluding sex hormones	30850	8.7
Respiratory system	9376	2.6
Antiparasitic products, insecticides, and repellents	4051	1.1
Antimalarials	1308	0.4
Antineoplastic and immunomodulating agents	1513	0.4
Blood and blood-forming organs	157	0.0
Musculoskeletal system	57	0.0
Genito-urinary system and sex hormones	61	0.0
Total	355574	100.0